Mounjaro NHS Criteria in 2026: What the Latest Guidance Actually Says

Which conditions count towards the NHS criteria, and how many do you need?

NICE's appraisal of tirzepatide, TA1026, lists five qualifying conditions: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. To qualify under the current NHS criteria, you need a BMI of 40 or above with at least four of those five, or (from 23 June 2026) a BMI between 35 and 39.9 with the same four-condition requirement. That second cohort opening is genuinely significant: it substantially widens the number of people who could be considered. However, possessing four conditions on that list does not automatically translate to a prescription. Every NHS patient must also engage with a supported diet and activity programme, and individual GP practices are deciding whether to participate in the new prescribing arrangement at all.

For anyone whose BMI sits between 30 and 34.9, or who has fewer than four of the five conditions, the NHS route is not currently open regardless of how long they have struggled with their weight. That is a reality that leaves a large number of people in a frustrating position, not because their health isn't affected, but because the phased rollout is deliberately cautious about NHS capacity. If you want to understand how the Mounjaro weight loss NHS criteria apply in practice, it is worth reading through them carefully if you're close to a threshold but unsure which side you fall on, alongside the full eligibility criteria.

What changed with the GP contract in April 2026, and does that mean your GP can prescribe it now?

From 1 April 2026, GP practices in England can prescribe tirzepatide directly as part of the updated QOF (Quality and Outcomes Framework) arrangements, rather than patients needing a referral to a specialist weight management service. This was a meaningful shift in access on paper. In practice, participation is optional for individual practices, and uptake has been uneven. Some practices are already offering it; others have not yet put the infrastructure (including the mandatory wraparound diet and lifestyle support) in place. Availability genuinely differs street by street, let alone region by region.

If your GP practice is participating, they will assess whether you meet the cohort criteria, discuss the wraparound care requirements, and initiate a prescription if you're clinically suitable. If your practice isn't yet involved, you may be told to wait or to seek a referral, which can take considerable time. The NHS England guidance on weight management injections sets out what the wraparound care should include and is worth bookmarking if you're pursuing the NHS route.

Scotland, Wales and Northern Ireland operate under different frameworks; the phases described here apply to England. Scottish criteria are administered via NHS Inform and differ in both thresholds and timelines.

What's the next phase, and when does it open?

The rollout has a published forward schedule. From around March 2027, the criteria are expected to widen again: adults with a BMI of 40 or above who have three (rather than four) of the qualifying conditions will become eligible. Subsequent phases (covering lower BMI thresholds and fewer co-existing conditions) are planned beyond that, though exact dates have not been confirmed. Each phase depends on NHS supply, prescriber capacity and the infrastructure that practices need to deliver the wraparound support. Dates have shifted before and may shift again.

For a more detailed breakdown of the phased cohorts and how the ethnic-background adjustments apply at each stage, the tirzepatide NHS criteria page maps out the full schedule. If you're wondering how the 2025 position compared to now, the 2025 criteria summary is still there for reference.

If you don't meet the NHS criteria right now, what are the options?

This is the question our prescribers hear most weeks, and it deserves a straight answer. If you don't qualify under the NHS criteria, or if your GP practice isn't yet set up to prescribe, a private prescription is the legal alternative. Mounjaro is a prescription-only medicine in any setting; the clinical assessment still has to happen, the difference is that a private service can move quickly and isn't gated by cohort criteria in the same way, provided you meet the licensed criteria from the SmPC (generally BMI ≥30, or ≥27 with a weight-related condition).

If you're considering the private route, understanding how to access it safely matters. Counterfeit tirzepatide pens have been seized in the UK, including from an illicit manufacturing site discovered in October 2025; the only safe way to obtain a prescription medicine is through a pharmacy you can verify on the GPhC register. Cost context is genuinely relevant too, how Mounjaro is priced privately has changed since Eli Lilly revised list prices upward in September 2025, and knowing what a realistic monthly cost looks like helps you plan. For a broader look at weight-loss treatment options and how they compare, that overview covers more than just Mounjaro.

If you'd like to explore whether private treatment is right for your situation, speaking to our prescribers is the starting point, a free consultation, reviewed by a GPhC-registered Independent Prescriber the same day.